Dementia and Cognitive Decline: An Integrated Analysis of Aetiology, Care, and Research Directions

rekhaboodoo
54 minutes ago
19 min read

Author: Rekha Boodoo-Lumbus

Affiliation: RAKHEE LB LIMITED, United Kingdom

AI-generated Image

Abstract

Dementia is best understood not as a single disease but as a clinical syndrome with a heterogeneous presentation with diverse aetiologies that progress towards cognitive and functional decline. This article synthesises contemporary evidence on dementia mechanisms, clinical presentation, and care practice, integrating the 7 A’s framework for symptom phenotyping and the Four R’s model for pragmatic, dignity centred care. It further examines prevention science and the 2026 research milieu, including blood based biomarkers, disease modifying therapeutics, and AI enabled early detection. By linking neuropathology to lived experience and care systems, the paper clarifies why aetiological precision, early assessment, and structured carer strategies are essential to improving outcomes for individuals and families affected by neurocognitive disorders.

Acknowledgements

The author acknowledges clinicians, researchers, caregivers, and people living with dementia whose experiences and scholarship continue to shape evidence based, dignity centred neurocognitive care. The interdisciplinary foundations of this work, spanning neurology, psychiatry, nursing, and public health, reflect the collective effort required to address dementia as both a biomedical and societal challenge. Any remaining errors of interpretation are the responsibility of the author.

Introduction: The Imperative of Early Definition

Despite a burgeoning consensus that neurocognitive disorders transcend any singular explanatory framework, dementia care and research remain siloed within disparate biological, psychological, and social paradigms. Recent breakthroughs in neuropathology, biomarker driven detection, and disease modifying therapies have significantly advanced our technical capabilities. However, these clinical milestones have largely outpaced the translation of such insights into the granular realities of longitudinal care. Consequently, a persistent disconnect remains between biological precision and the subjective lived experience of the patient. This article seeks to bridge this ontological gap by synthesising neuropathological mechanisms with sophisticated symptom phenotyping and psychologically informed care responses. By integrating the 7 A’s framework of clinical manifestation with the Four R’s model of intervention, this analysis establishes a unified trajectory, aligning diagnostic accuracy with a dignity-centred, ethically grounded approach to care across the disease continuum.

1. General Education and Awareness: Unpacking the Syndrome

Understanding Dementia: Causes, Symptoms, and Types

The aetiology of dementia is heterogeneous, and this heterogeneity is clinically consequential as a result of different pathologies produce different symptom profiles, rates of progression, and care needs (Scheltens et al., 2021; Knopman et al., 2021). At a mechanistic level, neurodegeneration commonly reflects the accumulation of misfolded proteins, synaptic dysfunction, neuroinflammation, and/or cerebrovascular injury, with mixed pathologies frequently observed in older adults show mixed AD and vascular or Lewy pathology at autopsy (Scheltens et al., 2021; see also Schneider et al., 2007; Rahimi et al., 2014), highlighting why aetiological precision matters. Symptoms are not random; they map onto the topological distribution of neuropathology, such that hippocampal and medial temporal involvement preferentially disrupts episodic memory, while fronto subcortical network compromise more strongly affects executive function, motivation, and behavioural regulation (Jack et al., 2010; Scheltens et al., 2021).

Clinically, the most prevalent dementia subtypes include Alzheimer’s disease (AD), vascular dementia (VaD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), each with characteristic cognitive behavioural signatures and differing implications for risk management and carer support (O’Brien & Thomas, 2015; Knopman et al., 2021). Importantly, diagnostic clarity is not simply academic: it shapes medication choices, anticipatory guidance, safeguarding decisions, and the timing of legal and financial planning (McKhann et al., 2011; Dubois et al., 2021).

Dementia vs. Alzheimer’s: Clarifying the Pathology

The conflation of dementia with Alzheimer’s disease remains a pervasive barrier to accurate understanding and timely care. Dementia describes the clinical syndrome, observable cognitive and functional decline, whereas Alzheimer’s disease is a specific neurodegenerative pathology defined by amyloid‑β deposition and tau‑mediated neurofibrillary change (Jack et al., 2018; Long & Holtzman, 2019). This distinction matters attributable to Alzheimer’s is common but not exclusive: Alzheimer’s pathology may coexist with vascular injury, Lewy body pathology, or other neurodegenerative processes, producing mixed presentations that can confuse families and clinicians if "dementia" is treated as a single entity (Scheltens et al., 2021; Teunissen et al., 2022).

Epidemiologically, Alzheimer’s disease is the leading cause of dementia and is often cited as accounting for 60 to 80% of cases. However, the proportion varies by population, diagnostic method, and the prevalence of mixed pathology (Livingston et al., 2024; Knopman et al., 2021). A precise distinction is required: dementia denotes the syndrome, Alzheimer’s represents one major underlying pathology, and many cases reflect mixed aetiologies that complicate categorical assumptions (Dubois et al., 2014; Jack et al., 2018).

The 7 A’s Framework: A Clinical Phenotype

To operationalise dementia symptomatology in a way that is clinically usable for both professionals and carers, the 7 A’s framework provides a structured phenotype that links observable impairments to underlying network degradation (standard clinical phenotype used in Canadian dementia training programmes such as P.I.E.C.E.S.™ and RNAO guidelines). Used carefully, it supports earlier recognition, clearer communication with families, and more targeted non‑pharmacological interventions particularly when behavioural symptoms are misread as "personality" rather than neurocognitive change (Kales et al., 2015; Gitlin et al., 2012).

Amnesia: Amnesia in dementia is typically most evident in short‑term episodic input processing and retrieval, reflecting early vulnerability of hippocampal and medial temporal structures in Alzheimer’s disease (Jack et al., 2010; Jack et al., 2018). Clinically, this presents as repetitive questioning, difficulty retaining new information, and increasing reliance on prompts, lists, or carer guidance (McKhann et al., 2011).
Aphasia: Aphasia ranges from subtle word finding difficulty to impaired comprehension and reduced semantic access, depending on the networks affected and the dementia subtype (Scheltens et al., 2021). Over time, language impairment can undermine social participation and increase carer burden insofar as communication breakdown often precedes overt functional dependence (Brodaty & Donkin, 2009).
Agnosia: Agnosia involves impaired recognition of objects, faces, or environmental cues despite intact primary sensory function, and it can contribute to distress, misinterpretation of surroundings, and heightened risk in unfamiliar environments (Scheltens et al., 2021). In practice, agnosia can look like "not trying" or "being difficult," which makes psychoeducation essential for reducing blame and conflict within families (Kales et al., 2015).
Apraxia: Apraxia reflects impaired execution of learned purposeful movements, affecting dressing, utensil use, sequencing of tasks, and safe mobility (Knopman et al., 2021). This has direct safeguarding implications, as apraxia increases falls risk, heightens kitchen related hazards, and leads to dependence in activities of daily living, even when memory appears relatively preserved (Rockwood et al., 2005).
Anosognosia: Anosognosia is a neurocognitive lack of insight into impairment, not a moral failure, and it frequently drives conflict around driving cessation, medication adherence, and acceptance of support (Rabinovici, 2019). Recognising anosognosia reframes "refusal" as a symptom, enabling carers to shift from confrontation to structured risk reduction and environmental adaptation (Gitlin et al., 2012).
Apathy: Apathy is a primary motivational deficit linked to frontal subcortical dysfunction and is associated with reduced initiation, emotional flattening, and withdrawal from previously meaningful activities (Fitten et al., 2023). It is often mislabelled as depression; while overlap exists, apathy may require different behavioural strategies and carer expectations (Fitten et al., 2023; Kales et al., 2015).
Altered perception: Altered perception includes hallucinations, delusions, and misinterpretations, and is particularly salient in Lewy body dementia and later stage Alzheimer’s disease (Scheltens et al., 2021). These symptoms can escalate carer stress and precipitate crisis admissions if not managed with careful environmental modification, reassurance, and clinical review of triggers such as infection, pain, or medication effects (Kales et al., 2015; Ballard et al., 2021).

The 10 Key Warning Signs

Early detection depends on identifying functional change relative to an individual’s baseline, rather than attributing concerns to simple "forgetfulness." Dementia is defined by impairment that disrupts everyday life and independence (Alzheimer’s Association, 2025; McKhann et al., 2011). The following warning signs are clinically useful in that they capture decline in instrumental activities, planning, judgement, navigation, and communication, domains that often deteriorate before overt dependence in basic self‑care emerges (Petersen, 2004; Petersen et al., 2018). In practice, these signs require interpretation alongside collateral history, risk context, and comorbidities, given the potential for reversible contributors (e.g., depression, medication effects, sensory loss) to mimic or exacerbate cognitive symptoms (Yaffe et al., 2014; Livingston et al., 2024).

Clinical indicators of early dementia

Disruptive memory loss affecting daily life Memory impairment extends beyond occasional forgetfulness to interfere with routine functioning, including missed appointments, repeated questioning, or reliance on external prompts for previously independent tasks.
Challenges in planning or executing complex problem‑solving Difficulties emerge in organising multi‑step activities, managing finances, or adapting to unexpected changes, reflecting impairment in executive functioning rather than isolated memory failure.
Difficulty completing familiar occupational or domestic tasks Individuals may struggle with tasks that were once automatic, such as preparing meals, operating household appliances, or fulfilling work‑related responsibilities, despite preserved physical ability.
Spatiotemporal disorientation (confusion with time or place) Disorientation may manifest as losing track of dates, seasons, or familiar routes, or becoming confused in previously well‑known environments, particularly under conditions of stress or fatigue.
Deficits in visual processing and spatial relationships Impairments include difficulty judging distances, recognising objects or faces, interpreting visual information, or navigating spatial layouts, increasing risk in activities such as driving or mobility.
New onset of linguistic withdrawal in speech or writing Language changes may involve word‑finding difficulties, reduced verbal output, circumlocution, or withdrawal from written communication, often misattributed to anxiety or low mood.
Misplacing items coupled with an inability to retrace steps Objects are placed in inappropriate locations, with diminished capacity to reconstruct actions or search logically, distinguishing this from benign forgetfulness.
Decreased or severely impaired judgement (e.g., financial vulnerability) Poor decision‑making may become evident through unsafe choices, susceptibility to scams, neglect of personal safety, or inappropriate social behaviour, carrying clear safeguarding implications.
Withdrawal from social, occupational, or recreational engagements Reduced participation often reflects cognitive overload, loss of confidence, or difficulty following conversations, rather than loss of interest alone.
Pronounced alterations in mood, affect, and personality Changes may include apathy, irritability, anxiety, disinhibition, or emotional lability, sometimes preceding overt cognitive decline and complicating differential diagnosis.

(Alzheimer’s Association, 2025; Petersen et al., 2018)

2. Carer Support and Practical Advice: Actionable Interventions

Non‑Pharmacological Strategies for Carers

The psychosocial burden of caring often outpaces the medical management of dementia, particularly when behavioural and psychological symptoms (BPSD) emerge and families lack a coherent explanatory model (Brodaty & Donkin, 2009; Kales et al., 2015). Evidence based dementia care therefore prioritises non‑pharmacological strategies as first‑line approaches, both where they address triggers and unmet needs and because pharmacological options for agitation and distress carry significant risk in frail older adults (Gitlin et al., 2012; Ballard et al., 2021). Supporting a person living with dementia frequently requires abandoning strict "reality orientation" in favour of validation informed communication, where the carer responds to the emotional truth of the experience rather than attempting to win factual disputes that the impaired brain cannot resolve (Kales et al., 2015).

Clinically, BPSD should be conceptualised as communication: agitation, wandering, repetitive questioning, or apparent "resistance" often reflect pain, fear, sensory overload, loneliness, fatigue, constipation, infection, or environmental mismatch (Kales et al., 2015; Mitchell et al., 2009). Behavioural expressions function as diagnostic signals, guiding assessment of antecedents, environmental demands, and support needs, rather than indicating intentional non‑compliance (Gitlin et al., 2012; Brodaty & Donkin, 2009).

The Four R’s of Dementia Care

The “Four R’s” describe a structured, repeatable approach to mitigating distress and optimising neuro‑environmental interactions in dementia care. This pragmatic framework synthesises widely taught, evidence‑informed carer strategies emphasised in professional dementia education, including guidance disseminated by the National Council of Certified Dementia Practitioners (NCCDP). Application across home, hospital, and care environments supports consistent caring responses, reducing variability that can contribute to escalation (Brodaty & Donkin, 2009; Kales et al., 2015; Gitlin et al., 2012)

Reassure: Reassurance functions as affect regulation. Even when declarative memory fails, emotional tone and perceived safety can persist, meaning calm validation can reduce amygdala‑driven threat responses and prevent escalation (Kales et al., 2015). Reassurance is most effective when paired with non‑verbal congruence, soft tone, slow pace, open posture due to the person may rely more on prosody and facial cues than on semantic content (Gitlin et al., 2012).
Routine: Routine reduces cognitive load by externalising structure. Predictable sequences compensate for impaired executive function and reduce the frequency of decision points that can trigger anxiety or frustration (Rockwood et al., 2005; Kales et al., 2015). Routine is not rigidity for its own sake; it provides a neuroprotective support mechanism that preserves autonomy for longer by reducing cognitive and environmental demands in daily life (Brodaty & Donkin, 2009).
Reminisce: Reminiscence draws on relatively preserved remote memory and identity‑linked narratives, supporting connection and reducing distress through familiarity (Brodaty & Donkin, 2009). When used skilfully, reminiscence functions not as distraction but as a therapeutic intervention that affirms continuity of self and can improve cooperation with care by restoring a sense of safety and trust (Gitlin et al., 2012).
Redirect: Redirection is a de‑escalation strategy informed by the recognition that impaired cognitive flexibility makes direct confrontation ineffective (Kales et al., 2015). Effective redirection involves shifting attention toward a neutral or calming stimulus, such as music, a simple activity, a brief walk, or a drink, while maintaining dignity and avoiding power struggles that commonly intensify agitation (Gitlin et al., 2012).

Navigating Late‑Stage Dementia

Late stage dementia represents a transition from cognitive preservation to comfort centred, palliative informed care, in which the clinical priority shifts toward relief of distress, prevention of avoidable complications, and support for family decision making (Mitchell et al., 2012). Advanced dementia is associated with profound functional dependence, dysphagia, weight loss, recurrent infections, and increased risk of aspiration pneumonia, often accompanied by reduced verbal communication and altered pain expression (Mitchell et al., 2009; Mitchell et al., 2012). At this stage, communication becomes primarily behavioural and somatic, requiring caregivers to interpret micro expressions, muscle tension, vocalisations, sleep disruption, and changes in appetite or mobility as potential indicators of discomfort or unmet need (Mitchell et al., 2009).

A rigorous care approach also requires anticipatory planning. Discussions regarding goals of care, hospital transfers, feeding decisions, and symptom management should occur early enough for the person’s values to be represented and for families to be supported through ethically complex choices (Mitchell et al., 2012). This is where dementia care intersects directly with safeguarding and dignity, ensuring that risk management does not become coercive and that comfort is not mistaken for giving up, but recognised as clinically appropriate care aligned with disease trajectory (Mitchell et al., 2012; World Health Organisation, 2023).

When to Seek a Professional Memory Assessment

Timely assessment is essential when cognitive lapses disrupt instrumental activities of daily living such as medication management, finances, cooking safety, navigation, or occupational functioning, as these changes signal clinically meaningful impairment rather than benign forgetfulness (Petersen, 2004; Petersen et al., 2018). Formal evaluation typically integrates clinical history, collateral information, cognitive testing, and functional assessment, with neuroimaging and biomarker informed pathways used where indicated, enabling more accurate aetiological classification and risk planning (McKhann et al., 2011; Dubois et al., 2021). Early assessment also facilitates access to clinical trials and emerging disease modifying therapies in appropriate populations, while allowing families to address legal, financial, and care planning before crisis points arise (Cummings et al., 2025; van Dyck et al., 2023).

3. Psychological Dimensions of Dementia: Identity, Emotion, and Meaning

Dementia is not solely a neurobiological process but a profound psychological experience that reshapes identity, emotional regulation, and interpersonal meaning. Cognitive decline disrupts autobiographical memory, narrative continuity, and self‑concept, often producing psychological distress that precedes or exceeds measurable functional impairment. From a psychological perspective, dementia challenges the coherence of the self, as individuals struggle to reconcile preserved emotional awareness with diminishing cognitive control, a phenomenon particularly evident in early and moderate stages of the syndrome (Kitwood, 1997; Rosenberg et al., 2020).

Emotional processing in dementia is frequently preserved longer than declarative memory, resulting in heightened sensitivity to environmental tone, relational dynamics, and perceived threat. This dissociation explains why individuals may forget events yet retain emotional reactions to them, reinforcing the importance of psychologically informed caregiving approaches that prioritise affective safety over factual correction (Brodaty & Donkin, 2009; Kales et al., 2015). Psychological distress in dementia therefore often manifests indirectly through agitation, withdrawal, or behavioural change, rather than through verbalised anxiety or low mood.

Psychological Impact on Carers and Support Systems

The psychological burden of dementia extends beyond the individual to carers and family systems, where chronic stress, anticipatory grief, and role captivity are common. Carers frequently experience ambiguous loss, in which the person is physically present but psychologically altered, producing grief without closure and complicating emotional adjustment (Brodaty and Donkin, 2009). This strain within caring systems can intensify behavioural symptoms in the person with dementia, creating reciprocal cycles of distress that are better understood through a psychological systems perspective rather than a purely medical model (Gitlin et al., 2012).

Psychologically informed interventions such as validation, reminiscence, and structured routine function not only as behavioural management strategies but also as mechanisms for preserving continuity of identity and emotional meaning. These approaches align closely with the Four Rs framework by recognising that emotional attunement, predictability, and affirmation of self remain central to psychological wellbeing even as cognitive capacity declines (Kales et al., 2015; Fitten et al., 2023).

Anosognosia, Insight, and Psychological Misinterpretation

Anosognosia occupies a critical intersection between neurology and psychology. While neurologically driven, lack of insight is often misinterpreted psychologically as denial, resistance, or personality change, leading to conflict and inappropriate expectations. A psychologically literate framing reframes anosognosia as a loss of metacognitive capacity rather than a defensive process, enabling caregivers and clinicians to adjust communication strategies and reduce moral judgement (Rabinovici, 2019). Understanding anosognosia through this dual lens supports ethical care planning, particularly in areas of consent, risk management, and safeguarding, where psychological assumptions about “choice” or “non‑compliance” can inadvertently undermine dignity and autonomy.

4. Current Research and Prevention: Forward Looking 2026 Trajectories

The 2026 Research Context

By 2026, dementia research has increasingly shifted from late stage symptom management toward earlier biological detection and intervention, reflecting the recognition that neuropathological change precedes clinical dementia by years or decades (Jack et al., 2010; Sperling et al., 2011). A central trajectory is "precision neurology," in which fluid biomarkers and imaging are used to phenotype disease processes more accurately, potentially enabling earlier, more targeted therapeutic strategies (Teunissen et al., 2022; Hansson et al., 2025). Blood based biomarkers, particularly phosphorylated tau species, are being positioned as scalable tools for primary care triage and risk stratification, with the aim of reducing diagnostic delay and improving pathway efficiency (Hansson et al., 2025; Zetterberg & Blennow, 2026).

This shift also reframes dementia as a continuum rather than a binary state, aligning with preclinical and prodromal staging models that integrate biomarker dynamics with clinical change (Sperling et al., 2011; Jack et al., 2018). However, it must also be acknowledged implementation complexity: biomarker availability, interpretive thresholds, comorbidity confounding, and equity of access remain active challenges as systems attempt to translate research tools into routine care (Teunissen et al., 2022; World Health Organization, 2023).

Modifiable Risk Factors and Prevention

Can lifestyle changes prevent dementia? The strongest contemporary consensus is that a substantial proportion of dementia cases may be preventable or delayable through modification of risk factors across the life course, with estimates commonly cited around 40 to 45% depending on modelling assumptions and population context (Livingston et al., 2024; Norton et al., 2014). Prevention science emphasises vascular and metabolic health, sensory impairment management, education and cognitive reserve, mental health treatment, and reduction of exposures that compound neuroinflammatory and cerebrovascular burden (Livingston et al., 2024; van der Flier & Scheltens, 2005). Importantly, prevention is not a moralised narrative of individual responsibility; it is a public health agenda requiring structural interventions, hearing care access, air quality policy, injury prevention, and equitable cardiovascular risk management (World Health Organization, 2023; Livingston et al., 2024).

Multidomain intervention trials provide empirical support for the plausibility of risk reduction, demonstrating that combined approaches (diet, exercise, cognitive training, vascular monitoring) can improve or preserve cognitive outcomes in at‑risk older adults (Ngandu et al., 2015; Rosenberg et al., 2020). Dietary patterns such as the MIND framework are often discussed as neuroprotective, particularly when embedded within broader cardiometabolic risk reduction rather than treated as isolated nutritional “fixes” (Kivipelto et al., 2018; Livingston et al., 2024). The most defensible PhD‑level conclusion is therefore conditional: prevention is meaningful, probabilistic, and population level, capable of shifting risk distributions even if it cannot guarantee individual immunity (Norton et al., 2014; Livingston et al., 2024).

Advances in Therapeutics: Beyond Symptom Management

The clinical introduction of anti‑amyloid monoclonal antibodies marked a transition toward disease modifying therapy (DMT) in early Alzheimer’s disease, with trials demonstrating amyloid clearance and modest slowing of cognitive decline in selected populations (van Dyck et al., 2023; Cummings et al., 2025). This development holds scientific significance through the operationalisation of the amyloid hypothesis into an actionable therapeutic pathway, while also intensifying debate regarding clinical meaningfulness, safety monitoring, and health system feasibility (Selkoe and Hardy, 2016; Cummings et al., 2025). In practice, DMT implementation requires careful patient selection, biomarker confirmation, and monitoring for adverse events, particularly amyloid‑related imaging abnormalities (ARIA), which complicate real‑world scalability (van Dyck et al., 2023; Cummings et al., 2025).

By 2026, research emphasis has expanded toward combinatorial and downstream targets, including tau‑directed strategies, neuroinflammation modulation, microglial pathway interventions, and metabolic approaches that address broader neurodegenerative cascades (Long & Holtzman, 2019; Cummings et al., 2020). This diversification reflects a maturing field: Alzheimer’s disease is increasingly conceptualised as a network disorder with multiple interacting biological drivers rather than a single‑pathway pathology (Masters et al., 2015; Knopman et al., 2021). The most credible forward trajectory is therefore integrative, combining earlier detection, multi‑target therapeutics, and prevention‑oriented public health measures rather than relying on any single “silver bullet” (Livingston et al., 2024; World Health Organization, 2023).

The Role of AI in Early Detection

Artificial intelligence and machine learning are increasingly positioned as tools for earlier, less invasive detection of cognitive change, particularly through analysis of speech, language, and behavioural signals that may shift subtly before clinical thresholds are crossed (Bzdok & Meyer‑Lindenberg, 2018). Natural language processing approaches can detect micro‑changes in syntax, semantics, and discourse coherence, while multimodal models integrating imaging, retinal measures, and digital phenotypes aim to improve predictive accuracy and triage efficiency (Weiner et al., 2013; Bzdok & Meyer‑Lindenberg, 2018). These approaches are attractive due to their promise scalability and earlier identification, potentially widening access to assessment pathways in under‑resourced settings (World Health Organisation, 2023).

A rigorous academic framing must also address governance: AI enabled screening raises questions about bias, false positives, consent, privacy, and the psychological impact of risk labelling especially when disease modifying options remain limited or access is unequal (World Health Organisation, 2023; Bzdok & Meyer‑Lindenberg, 2018). The most defensible position is therefore cautious optimism: AI may enhance detection and monitoring, but its ethical deployment depends on transparent validation, equitable implementation, and clinically meaningful pathways that translate “risk signals” into supportive, person centred care (Weiner et al., 2013; World Health Organization, 2023).

Conclusion

The evidence presented here highlights that dementia is a multifaceted syndrome, requiring a healthcare response as complex as the neuropathology itself. Recognising this heterogeneity is critical; it is the foundation upon which we must build more effective diagnostic protocols and health system infrastructures. Understanding the biological substrates of cognitive change is not just a scientific exercise, it is the key to predicting symptom trajectories and implementing interventions that actually meet a patient's specific needs. The integration of the 7 A’s and the Four R’s serves as a vital bridge in this process. While the 7 A's provide a structured way to categorise symptoms, the Four R's offer a practical, compassionate pathway for carers to respond to those symptoms in a way that preserves the individual's dignity. This combination ensures that neuroscientific insight is never separated from ethically grounded practice. As we stand on the threshold of a new era defined by AI driven detection and advanced biomarkers, we must remain vigilant. While these technologies offer unprecedented opportunities for early, stratified intervention, they must not lead to a 'technological takeover' of care. The enduring imperative remains a balance of progress and personhood. We must strive for a future where increasing biological accuracy serves to strengthen the relational bonds between patient and provider, ensuring that innovation always leads back to more compassionate, person-centred care.

References

Alzheimer's Association. (2025). Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia.
Ballard, C., et al. (2021). Management of Agitation and Aggression Associated with Alzheimer Disease. Nature Reviews Neurology.
Barnes, D. E., & Yaffe, K. (2011). The Projected Effect of Risk Factor Reduction on Alzheimer's Disease Prevalence. The Lancet Neurology.
Bateman, R. J., et al. (2012). Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine.
Blennow, K., & Zetterberg, H. (2018). Biomarkers for Alzheimer's Disease: Current Status and Prospects for the Future. Journal of Internal Medicine.
Brodaty, H., & Donkin, M. (2009). Family Caregivers of People with Dementia. Dialogues in Clinical Neuroscience.
Bzdok, D., & Meyer-Lindenberg, A. (2018). Machine Learning for Precision Psychiatry: Opportunities and Challenges. Biological Psychiatry.
Cummings, J. L. (2004). Alzheimer's Disease. New England Journal of Medicine.
Cummings, J., et al. (2020). Alzheimer's Disease Drug Development Pipeline. Alzheimer's & Dementia: Translational Research & Clinical Interventions.
Cummings, J., et al. (2025). The State of Alzheimer's Disease Therapeutics 2025. Alzheimer's & Dementia.
Dubois, B., et al. (2014). Advancing Research Diagnostic Criteria for Alzheimer's Disease: The IWG-2 Criteria. The Lancet Neurology.
Dubois, B., et al. (2021). Clinical Diagnosis of Alzheimer's Disease: Recommendations of the International Working Group. The Lancet Neurology.
Fitten, L. J., et al. (2023). Apathy in Neurodegenerative Diseases: Neurobiological Substrates and Therapeutic Interventions. Journal of Clinical Psychiatry.
Frisoni, G. B., et al. (2010). The Clinical Use of Structural MRI in Alzheimer Disease. Nature Reviews Neurology.
Gitlin, L. N., et al. (2012). Nonpharmacologic Management of Behavioral Symptoms in Dementia. JAMA.
Hardy, J., & Selkoe, D. J. (2002). The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. Science.
Hansson, O., et al. (2025). Blood-Based Biomarkers for the Diagnosis of Alzheimer's Disease in Primary Care. Nature Medicine.
Jack, C. R., et al. (2010). Hypothetical Model of Dynamic Biomarkers of the Alzheimer's Pathological Cascade. The Lancet Neurology.
Jack, C. R., et al. (2018). NIA-AA Research Framework: Toward a Biological Definition of Alzheimer's Disease. Alzheimer's & Dementia.
Kales, H. C., et al. (2015). Assessment and Management of Behavioral and Psychological Symptoms of Dementia. The BMJ.
Kitwood, T. (1997). Dementia Reconsidered: The Person Comes First. Open University Press.
Kivipelto, M., et al. (2018). Lifestyle Interventions to Prevent Cognitive Impairment, Dementia and Alzheimer Disease. Nature Reviews Neurology.
Knopman, D. S., et al. (2021). Alzheimer Disease. Nature Reviews Disease Primers.
Lancet Commission. (2020). Dementia Prevention, Intervention, and Care: 2020 Report. The Lancet.
Livingston, G., et al. (2024). Dementia Prevention, Intervention, and Care: 2024 Report of the Lancet Standing Commission. The Lancet.
Long, J. M., & Holtzman, D. M. (2019). Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell.
Masters, C. L., et al. (2015). Alzheimer's Disease. Nature Reviews Disease Primers.
McKhann, G. M., et al. (2011). The Diagnosis of Dementia Due to Alzheimer's Disease: Recommendations from the NIA-AA Workgroups. Alzheimer's & Dementia.
Mitchell, S. L., et al. (2009). The Clinical Course of Advanced Dementia. New England Journal of Medicine.
Mitchell, S. L., et al. (2012). Palliative Care for Patients with Advanced Dementia. JAMA.
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): Current Version and Scoring Rules. Neurology.
Ngandu, T., et al. (2015). A 2 Year Multidomain Intervention of Diet, Exercise, Cognitive Training, and Vascular Risk Monitoring (FINGER). The Lancet.
Norton, S., et al. (2014). Potential for Primary Prevention of Alzheimer's Disease: An Analysis of Population-Based Data. The Lancet Neurology.
O'Brien, J. T., & Thomas, A. (2015). Vascular Dementia. The Lancet.
Petersen, R. C. (2004). Mild Cognitive Impairment as a Diagnostic Entity. Journal of Internal Medicine.
Petersen, R. C., et al. (2018). Practice Guideline Update Summary: Mild Cognitive Impairment. Neurology.
Rabinovici, G. D. (2019). Late-Onset Alzheimer Disease. Continuum: Lifelong Learning in Neurology.
Rockwood, K., et al. (2005). A Global Clinical Measure of Fitness and Frailty in Elderly People. CMAJ.
Rosenberg, A., et al. (2020). Multidomain Interventions to Prevent Cognitive Impairment and Dementia. Journal of Prevention of Alzheimer's Disease.
Scheltens, P., et al. (2021). Alzheimer's Disease. The Lancet.
Selkoe, D. J., & Hardy, J. (2016). The Amyloid Hypothesis of Alzheimer's Disease at 25 Years. EMBO Molecular Medicine.
Sperling, R. A., et al. (2011). Toward Defining the Preclinical Stages of Alzheimer's Disease: Recommendations from the NIA-AA Workgroups. Alzheimer's & Dementia.
Sperling, R. A., et al. (2014). The Impact of Amyloid-Beta and Tau on Prospective Cognitive Decline in Older Individuals. Annals of Neurology.
Tariq, S. H., et al. (2006). The Saint Louis University Mental Status (SLUMS) Examination for Detecting Mild Cognitive Impairment. American Journal of Geriatric Psychiatry.
Teunissen, C. E., et al. (2022). Blood-Based Biomarkers for Alzheimer's Disease: Towards Clinical Implementation. The Lancet Neurology.
van der Flier, W. M., & Scheltens, P. (2005). Epidemiology and Risk Factors of Dementia. Journal of Neurology, Neurosurgery & Psychiatry.
van Dyck, C. H., et al. (2023). Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine.
Weiner, M. W., et al. (2013). The Alzheimer's Disease Neuroimaging Initiative: A Review of Papers Published Since Its Inception. Alzheimer's & Dementia.
World Health Organization. (2023). Global Status Report on the Public Health Response to Dementia. WHO Press.
Zetterberg, H., & Blennow, K. (2026). The Evolution of Fluid Biomarkers in Neurodegenerative Disease: A 2026 Perspective. Molecular Neurodegeneration.